Raiffeisen Bank International AG Has $41,000 Stock Holdings in Waters Corporation $WAT

Raiffeisen Bank International AG trimmed its position in shares of Waters Corporation (NYSE:WAT) by 97.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 111 shares of the medical instruments supplier’s stock after selling 4,744 shares during the quarter. Raiffeisen Bank International AG’s holdings in Waters were worth $41,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Zions Bancorporation National Association UT increased its position in shares of Waters by 121.2% in the 4th quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 40 shares in the last quarter. PenderFund Capital Management Ltd. bought a new position in Waters during the second quarter worth about $28,000. First Bancorp Inc ME bought a new position in Waters during the second quarter worth about $30,000. Caitlin John LLC grew its stake in Waters by 43.9% in the second quarter. Caitlin John LLC now owns 82 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 25 shares during the period. Finally, SHP Wealth Management acquired a new position in Waters in the fourth quarter valued at about $32,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

Wall Street Analysts Forecast Growth

WAT has been the topic of a number of research analyst reports. Sanford C. Bernstein assumed coverage on Waters in a research report on Friday, June 26th. They set an “outperform” rating and a $435.00 price target on the stock. Piper Sandler upgraded Waters from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $400.00 to $480.00 in a research report on Thursday, August 27th. TD Cowen raised Waters from a “hold” rating to a “buy” rating and increased their target price for the stock from $408.00 to $475.00 in a research note on Wednesday, August 5th. Citigroup raised their target price on shares of Waters from $425.00 to $470.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Wells Fargo & Company lifted their price target on shares of Waters from $370.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $424.35.

Insiders Place Their Bets

In other Waters news, Director Christopher Kuebler sold 3,626 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the completion of the transaction, the director owned 17,808 shares of the company’s stock, valued at $7,086,515.52. This represents a 16.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.31% of the stock is currently owned by company insiders.

Waters News Roundup

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Shares are up 3.1% since the company’s most recent earnings report, reflecting investor confidence after Waters exceeded quarterly expectations with adjusted EPS of $3.05 versus the $3.01 consensus and revenue of $1.65 billion versus $1.62 billion expected. Why Is Waters Up Since Last Earnings Report?
• Positive Sentiment: Analysts currently assign Waters a consensus recommendation of “Moderate Buy,” providing continued support for the stock. The company also maintained 2026 earnings guidance of $14.45 to $14.65 per share. Waters Given Moderate Buy Recommendation
• Neutral Sentiment: Waters’ latest results included strong reported year-over-year revenue growth and an earnings beat, but investors may focus on whether that momentum is sustainable and whether the company can deliver its full-year outlook.
• Negative Sentiment: The stock trades at a very elevated valuation—approximately 102 times earnings—so expectations are high. Any weaker-than-expected demand, guidance revision, or margin pressure could produce volatility despite the positive analyst consensus.

Waters Stock Performance

Shares of Waters stock opened at $409.39 on Monday. The firm has a market cap of $40.22 billion, a price-to-earnings ratio of 102.09, a price-to-earnings-growth ratio of 2.38 and a beta of 1.19. The stock’s 50-day moving average is $391.93 and its 200-day moving average is $351.64. Waters Corporation has a one year low of $282.77 and a one year high of $426.22. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.86 and a quick ratio of 1.29.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, topping the consensus estimate of $3.01 by $0.04. Waters had a return on equity of 11.27% and a net margin of 3.58%.The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.62 billion. During the same period in the prior year, the firm earned $2.95 earnings per share. Waters’s revenue for the quarter was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Equities analysts predict that Waters Corporation will post 14.56 earnings per share for the current fiscal year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.